Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Metformin in adults with type 1 diabetes : Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial. / Petrie, John R; Chaturvedi, Nish; Ford, Ian; Hramiak, Irene; Hughes, Alun D; Jenkins, Alicia J; E Klein, Barbara; Klein, Ron; Ooi, Teik Chye; Rossing, Peter; Sattar, Naveed; Stehouwer, Coen D A; Colhoun, Helen M; REMOVAL Trial Team.
I: Diabetes, Obesity and Metabolism, Bind 19, Nr. 4, 04.2017, s. 509-516.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Metformin in adults with type 1 diabetes
T2 - Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial
AU - Petrie, John R
AU - Chaturvedi, Nish
AU - Ford, Ian
AU - Hramiak, Irene
AU - Hughes, Alun D
AU - Jenkins, Alicia J
AU - E Klein, Barbara
AU - Klein, Ron
AU - Ooi, Teik Chye
AU - Rossing, Peter
AU - Sattar, Naveed
AU - Stehouwer, Coen D A
AU - Colhoun, Helen M
AU - REMOVAL Trial Team
N1 - © 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
PY - 2017/4
Y1 - 2017/4
N2 - AIMS: Cardiovascular (CV) disease is a major cause of reduced life expectancy in type 1 diabetes (T1D). Intensive insulin therapy prevents CV complications but is constrained by hypoglycaemia and weight gain. Adjunct metformin reduces insulin dose requirement and stabilizes weight but there are no data on its cardiovascular effects. We have therefore initiated an international double-blind, randomized, placebo-controlled trial (REMOVAL: REducing with MetfOrmin Vascular Adverse Lesions in type 1 diabetes) to examine whether metformin reduces progression of atherosclerosis in adults with T1D. Individuals ≥40 years of age with T1D for ≥5 years are eligible if they have ≥3 of 10 specified CV risk factors. The enrolment target is 500 participants in 17 international centres.MATERIALS AND METHODS: After 12 weeks of single-blind placebo-controlled run-in, participants with ≥ 70% adherence are randomized to metformin or matching placebo for 3 years with insulin titrated towards HbA1c 7.0% (53 mmol/mol). The primary endpoint is progression of averaged mean far wall common carotid intima-media thickness (cIMT) measured by ultrasonography at baseline, 12, 24 and 36 months. This design provides 90% power to detect a mean difference of 0.0167 mm in cIMT progression between treatment arms (α = 0.05), assuming that up to 20% withdraw or discontinue treatment. Other endpoints include HbA1c, weight, LDL cholesterol, insulin requirement, progression of retinopathy, endothelial function and frequency of hypoglycaemia.CONCLUSION: REMOVAL is the largest clinical trial of adjunct metformin therapy in T1D to date and will provide clinically meaningful information on its potential to impact CV disease and other complications.
AB - AIMS: Cardiovascular (CV) disease is a major cause of reduced life expectancy in type 1 diabetes (T1D). Intensive insulin therapy prevents CV complications but is constrained by hypoglycaemia and weight gain. Adjunct metformin reduces insulin dose requirement and stabilizes weight but there are no data on its cardiovascular effects. We have therefore initiated an international double-blind, randomized, placebo-controlled trial (REMOVAL: REducing with MetfOrmin Vascular Adverse Lesions in type 1 diabetes) to examine whether metformin reduces progression of atherosclerosis in adults with T1D. Individuals ≥40 years of age with T1D for ≥5 years are eligible if they have ≥3 of 10 specified CV risk factors. The enrolment target is 500 participants in 17 international centres.MATERIALS AND METHODS: After 12 weeks of single-blind placebo-controlled run-in, participants with ≥ 70% adherence are randomized to metformin or matching placebo for 3 years with insulin titrated towards HbA1c 7.0% (53 mmol/mol). The primary endpoint is progression of averaged mean far wall common carotid intima-media thickness (cIMT) measured by ultrasonography at baseline, 12, 24 and 36 months. This design provides 90% power to detect a mean difference of 0.0167 mm in cIMT progression between treatment arms (α = 0.05), assuming that up to 20% withdraw or discontinue treatment. Other endpoints include HbA1c, weight, LDL cholesterol, insulin requirement, progression of retinopathy, endothelial function and frequency of hypoglycaemia.CONCLUSION: REMOVAL is the largest clinical trial of adjunct metformin therapy in T1D to date and will provide clinically meaningful information on its potential to impact CV disease and other complications.
KW - Adult
KW - Atherosclerosis/drug therapy
KW - Blood Glucose/drug effects
KW - Body Weight/drug effects
KW - Carotid Intima-Media Thickness
KW - Cholesterol, LDL/blood
KW - Clinical Protocols
KW - Diabetes Mellitus, Type 1/blood
KW - Disease Progression
KW - Double-Blind Method
KW - Drug Therapy, Combination
KW - Female
KW - Glycated Hemoglobin A/drug effects
KW - Humans
KW - Hypoglycemia/chemically induced
KW - Hypoglycemic Agents/administration & dosage
KW - Insulin/administration & dosage
KW - Male
KW - Metformin/administration & dosage
KW - Middle Aged
KW - Risk Factors
KW - Single-Blind Method
U2 - 10.1111/dom.12840
DO - 10.1111/dom.12840
M3 - Journal article
C2 - 27935183
VL - 19
SP - 509
EP - 516
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 4
ER -
ID: 193963655